Milligest (Ethinylestradiol, Gestodene)

Ethinylestradiol, the active ingredient in Milligest, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Milligest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milligest is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

- Prevention of pregnancy: provides reliable contraception for women of child‑bearing potential. - Menstrual cycle regulation: helps achieve more predictable and lighter periods. - Acne management: may improve mild acne associated with androgen excess. - Endometriosis symptom control: reduces menstrual pain and lesion progression.

Common side effects are usually mild and transient, reflecting the hormonal activity of the preparation.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Spotting or breakthrough bleeding: irregular light bleeding. - Weight gain: modest fluid retention. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Stroke or myocardial infarction: especially in smokers over 35. - Severe hypertension: sudden increase in blood pressure. - Liver dysfunction: jaundice or abnormal liver enzymes. - Allergic reaction: rash, itching, swelling of face or throat.

Before prescribing Milligest, clinicians should assess individual risk factors and counsel patients on safe use.

- Smoking status: avoid in women over 35 who smoke due to increased thrombotic risk. - Cardiovascular disease: contraindicated in patients with history of stroke, myocardial infarction, or uncontrolled hypertension. - Liver disease: use with caution in active liver disease or severe hepatic impairment. - Pregnancy and lactation: not indicated; discuss alternative contraception if pregnancy is suspected. - Drug interactions: review concomitant medications that may affect hormonal efficacy. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Milligest may interact with other medicines that influence hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive effectiveness. - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Certain antiretrovirals (e.g., protease inhibitors): can alter hormone levels.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole): may increase hormone concentrations. - St. John’s wort: may modestly reduce efficacy. - Seizure medications (e.g., phenytoin): may require additional contraceptive measures.